How many drugs treat Prevention of Breast Carcinoma?

Drug Landscape tracks 3 marketed treatments for Prevention of Breast Carcinoma (deduplicated by molecule). 0 Phase 3 candidates and 0 Phase 2 candidates are in the pipeline.

How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/prevention-of-breast-carcinoma.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Prevention of Breast Carcinoma — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Prevention of Breast Carcinoma (disease) competitive landscape: 3 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

3 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Prevention of Breast Carcinoma, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Evista	RALOXIFENE	Eli Lilly	Estrogen Agonist/Antagonist	estrogen receptors	1997-01-01
Nolvadex	tamoxifen	AstraZeneca (originally ICI)	SERM (Selective estrogen receptor modulator)	Aldehyde oxidase, 3-beta-hydroxysteroid-Delta(8),Delta(7)-isomerase, 5-hydroxytryptamine receptor 6	1977-12-30
raloxifen	raloxifen	Organon and Co		Aldehyde oxidase, HLA class I histocompatibility antigen, A-3 alpha chain, 3-beta-hydroxysteroid-Delta(8),Delta(7)-isomerase

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

AstraZeneca (originally ICI) · 1 drug in Prevention of Breast Carcinoma
Eli Lilly · 1 drug in Prevention of Breast Carcinoma
Organon and Co · 1 drug in Prevention of Breast Carcinoma

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Prevention of Breast Carcinoma:

Cite this brief

Drug Landscape (2026). Prevention of Breast Carcinoma — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/prevention-of-breast-carcinoma. Accessed 2026-06-10.

Prevention of Breast Carcinoma full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing